Company intelligence / Profile preview
RQ Biotechnology Ltd
- Ownership
- Private
- Development stage
- Other
Overview
The first discovered monoclonal antibody by RQ Bio, AZD3152, entered clinical trials within less than a year after discovery as part of AstraZeneca’s SUPERNOVA Phase I/III trial evaluating safety and neutralizing activity against COVID‑19. This rapid progression demonstrates the effectiveness of their antibody discovery platform. Other pipeline programs remain in preclinical stages targeting influenza, CMV, RSV[1][4][8].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodies (mAbs), broad-spectrum neutralizing antibodiesAntibody therapeutics primarily for passive immunization against viral infections
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on RQ Biotechnology Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RQ Biotechnology Ltd.